Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers

Niamh Fitzgerald(Eolas (Ireland)), Jim McCambridge(University College Dublin), Nick Heather(UNSW Sydney), Kathryn Angus(University of Stirling), Marisa de Andrade(University of Edinburgh), Duncan Raistrick(University of Leeds), Andrew Elders(Glasgow Caledonian University)
Addiction
June 5, 2016
Cited by 42


Related Papers